<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T19:57:43Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:4519989" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:4519989</identifier><datestamp>2015-09-04</datestamp><setSpec>npgopen</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Nat Commun</journal-id>
      <journal-id journal-id-type="iso-abbrev">Nat Commun</journal-id>
      <journal-title-group>
        <journal-title>Nature Communications</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2041-1723</issn>
      <publisher>
        <publisher-name>Nature Publishing Group</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC4519989</article-id>
      <article-id pub-id-type="pmcid">PMC4519989</article-id>
      <article-id pub-id-type="pmc-uid">4519989</article-id>
      <article-id pub-id-type="pmid">26216346</article-id>
      <article-id pub-id-type="pii">ncomms8870</article-id>
      <article-id pub-id-type="doi">10.1038/ncomms8870</article-id>
      <article-id pub-id-type="pmid">26216346</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Mutations in <italic>CDCA7</italic> and <italic>HELLS</italic> cause immunodeficiencyâcentromeric instabilityâfacial anomalies syndrome</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Thijssen</surname>
            <given-names>Peter E.</given-names>
          </name>
          <xref ref-type="aff" rid="a1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ito</surname>
            <given-names>Yuya</given-names>
          </name>
          <xref ref-type="aff" rid="a2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Grillo</surname>
            <given-names>Giacomo</given-names>
          </name>
          <xref ref-type="aff" rid="a3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>Jun</given-names>
          </name>
          <xref ref-type="aff" rid="a1">1</xref>
          <xref ref-type="author-notes" rid="n1">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Velasco</surname>
            <given-names>Guillaume</given-names>
          </name>
          <xref ref-type="aff" rid="a3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nitta</surname>
            <given-names>Hirohisa</given-names>
          </name>
          <xref ref-type="aff" rid="a2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Unoki</surname>
            <given-names>Motoko</given-names>
          </name>
          <xref ref-type="aff" rid="a2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yoshihara</surname>
            <given-names>Minako</given-names>
          </name>
          <xref ref-type="aff" rid="a4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Suyama</surname>
            <given-names>Mikita</given-names>
          </name>
          <xref ref-type="aff" rid="a4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sun</surname>
            <given-names>Yu</given-names>
          </name>
          <xref ref-type="aff" rid="a1">1</xref>
          <xref ref-type="author-notes" rid="n2">â </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lemmers</surname>
            <given-names>Richard J. L. F.</given-names>
          </name>
          <xref ref-type="aff" rid="a1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>de Greef</surname>
            <given-names>Jessica C.</given-names>
          </name>
          <xref ref-type="aff" rid="a1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gennery</surname>
            <given-names>Andrew</given-names>
          </name>
          <xref ref-type="aff" rid="a5">5</xref>
          <xref ref-type="aff" rid="a6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Picco</surname>
            <given-names>Paolo</given-names>
          </name>
          <xref ref-type="aff" rid="a7">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kloeckener-Gruissem</surname>
            <given-names>Barbara</given-names>
          </name>
          <xref ref-type="aff" rid="a8">8</xref>
          <xref ref-type="aff" rid="a9">9</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>GÃ¼ngÃ¶r</surname>
            <given-names>Tayfun</given-names>
          </name>
          <xref ref-type="aff" rid="a10">10</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Reisli</surname>
            <given-names>Ismail</given-names>
          </name>
          <xref ref-type="aff" rid="a11">11</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Picard</surname>
            <given-names>Capucine</given-names>
          </name>
          <xref ref-type="aff" rid="a12">12</xref>
          <xref ref-type="aff" rid="a13">13</xref>
          <xref ref-type="aff" rid="a14">14</xref>
          <xref ref-type="aff" rid="a15">15</xref>
          <xref ref-type="aff" rid="a16">16</xref>
          <xref ref-type="aff" rid="a17">17</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kebaili</surname>
            <given-names>Kamila</given-names>
          </name>
          <xref ref-type="aff" rid="a18">18</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Roquelaure</surname>
            <given-names>Bertrand</given-names>
          </name>
          <xref ref-type="aff" rid="a19">19</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Iwai</surname>
            <given-names>Tsuyako</given-names>
          </name>
          <xref ref-type="aff" rid="a20">20</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kondo</surname>
            <given-names>Ikuko</given-names>
          </name>
          <xref ref-type="aff" rid="a21">21</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kubota</surname>
            <given-names>Takeo</given-names>
          </name>
          <xref ref-type="aff" rid="a22">22</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>van Ostaijen-Ten Dam</surname>
            <given-names>Monique M.</given-names>
          </name>
          <xref ref-type="aff" rid="a23">23</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>van Tol</surname>
            <given-names>Maarten J. D.</given-names>
          </name>
          <xref ref-type="aff" rid="a23">23</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Weemaes</surname>
            <given-names>Corry</given-names>
          </name>
          <xref ref-type="aff" rid="a24">24</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Francastel</surname>
            <given-names>Claire</given-names>
          </name>
          <xref ref-type="corresp" rid="c1">a</xref>
          <xref ref-type="aff" rid="a3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>van der Maarel</surname>
            <given-names>SilvÃ¨re M.</given-names>
          </name>
          <xref ref-type="corresp" rid="c2">b</xref>
          <xref ref-type="aff" rid="a1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sasaki</surname>
            <given-names>Hiroyuki</given-names>
          </name>
          <xref ref-type="corresp" rid="c3">c</xref>
          <xref ref-type="aff" rid="a2">2</xref>
        </contrib>
        <aff id="a1"><label>1</label><institution>Department of Human Genetics, Leiden University Medical Center</institution>, Leiden 2333ZA, <country>The Netherlands</country></aff>
        <aff id="a2"><label>2</label><institution>Division of Epigenomics and Development, Department of Molecular Genetics, Medical Institute of Bioregulation, Kyushu University</institution>, Fukuoka 812-8582, <country>Japan</country></aff>
        <aff id="a3"><label>3</label><institution>CNRS UMR7216, Epigenetics and Cell Fate, UniversitÃ© Paris Diderot, Sorbonne Paris CitÃ©</institution>, 75205 Paris, <country>France</country></aff>
        <aff id="a4"><label>4</label><institution>Division of Bioinformatics, Department of Multi-scale Research Center for Medical Science, Medical Institute of Bioregulation, Kyushu University</institution>, Fukuoka 812-8582, <country>Japan</country></aff>
        <aff id="a5"><label>5</label><institution>Department of Paediatric Immunology, Newcastle Upon Tyne Hospital, NHS Foundation Trust</institution>, Newcastle Upon Tyne, <country>UK</country></aff>
        <aff id="a6"><label>6</label><institution>Institute of Cellular Medicine, Newcastle University</institution>, Newcastle Upon Tyne NE1 4LP, <country>UK</country></aff>
        <aff id="a7"><label>7</label><institution>Division of Pediatrics and Pediatric Rheumatology, G. Gaslini Scientific Institute</institution>, Genova 16147, <country>Italy</country></aff>
        <aff id="a8"><label>8</label><institution>Institute of Medical Molecular Genetics, University of Zurich</institution>, Schlieren 8952, <country>Switzerland</country></aff>
        <aff id="a9"><label>9</label><institution>Department of Biology, ETH Zurich</institution>, Zurich 8093, <country>Switzerland</country></aff>
        <aff id="a10"><label>10</label><institution>Department of Oncology, University Childrenâs Hospital</institution>, Zurich 8032, <country>Switzerland</country></aff>
        <aff id="a11"><label>11</label><institution>Department of Pediatric Immunology and Allergy, Necmettin Erbakan University, Meram Medical Faculty</institution>, Konya 42080, <country>Turkey</country></aff>
        <aff id="a12"><label>12</label><institution>Centre de RÃ©fÃ©rence DÃ©ficits Immunitaires HÃ©rÃ©ditaires, AP-HP</institution>, 75743 Paris, <country>France</country></aff>
        <aff id="a13"><label>13</label><institution>Centre dâEtude des DÃ©ficits Immunitaires, HÃ´pital Universitaire Necker-Enfants Malades, AP-HP</institution>, 75743 Paris, <country>France</country></aff>
        <aff id="a14"><label>14</label><institution>Laboratoire de GÃ©nÃ©tique Humaine des Maladies Infectieuses, Inserm</institution>, 75743, Paris, <country>France</country></aff>
        <aff id="a15"><label>15</label><institution>UniversitÃ© Paris Descartes, Institut Imagine, Sorbonne Paris</institution>, 75743 Paris, <country>France</country></aff>
        <aff id="a16"><label>16</label><institution>UnitÃ© d'immunologie et dâhÃ©matologie pÃ©diatrique, HÃ´pital Necker-Enfants Malades</institution>, 75743, Paris, <country>France</country></aff>
        <aff id="a17"><label>17</label><institution>Inserm UMR 768</institution>, 75015 Paris, <country>France</country></aff>
        <aff id="a18"><label>18</label><institution>Centre de RÃ©fÃ©rence DÃ©ficits Immunitaires HÃ©rÃ©ditaires, Institut dâHÃ©matologie et dâOncologie PÃ©diatrique, CHU de Lyon</institution>, 69008 Lyon, <country>France</country></aff>
        <aff id="a19"><label>19</label><institution>Service dâhÃ©pato-gastro-entÃ©rologie et nutrition, endocrinologie et nÃ©phrologie pÃ©diatriques, HÃ´pital de la Timone, CHU Marseille</institution>, 13385 Marseille, <country>France</country></aff>
        <aff id="a20"><label>20</label><institution>Department of Pediatric Hematology and Oncology, Shikoku Medical Center for Children and adults</institution>, Kagawa 765-8507, <country>Japan</country></aff>
        <aff id="a21"><label>21</label><institution>Department of Pediatrics, Ooida Hospital</institution>, Kochi 788-0001, <country>Japan</country></aff>
        <aff id="a22"><label>22</label><institution>Department of Epigenetic Medicine, Faculty of Medicine, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi</institution>, Yamanashi 409-3898, <country>Japan</country></aff>
        <aff id="a23"><label>23</label><institution>Department of Pediatrics, Laboratory for Immunology, Leiden University Medical Center</institution>, Leiden 2333ZA, <country>The Netherlands</country></aff>
        <aff id="a24"><label>24</label><institution>Department of Pediatric Infectious Diseases and Immunology, Radboud University Nijmegen Medical Center</institution>, Nijmegen 6500HC, <country>The Netherlands</country></aff>
      </contrib-group>
      <author-notes>
        <corresp id="c1">
          <label>a</label>
          <email>claire.francastel@univ-paris-diderot.fr</email>
        </corresp>
        <corresp id="c2">
          <label>b</label>
          <email>Maarel@lumc.nl</email>
        </corresp>
        <corresp id="c3">
          <label>c</label>
          <email>hsasaki@bioreg.kyushu-u.ac.jp</email>
        </corresp>
        <fn id="n1">
          <label>*</label>
          <p>Present address: Institutes of Biology and Medical Sciences, Soochow University, Suzhou 215123, China</p>
        </fn>
        <fn id="n2">
          <label>â </label>
          <p>Present address: Shanghai Institute for Pediatric Research, Xin Hua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub">
        <day>28</day>
        <month>07</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2015</year>
      </pub-date>
      <volume>6</volume>
      <elocation-id>7870</elocation-id>
      <history>
        <date date-type="received">
          <day>02</day>
          <month>03</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>19</day>
          <month>06</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright Â© 2015, Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.</copyright-statement>
        <copyright-year>2015</copyright-year>
        <copyright-holder>Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          <!--author-paid-->
          <license-p>This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the articleâs Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link></license-p>
        </license>
      </permissions>
      <abstract>
        <p>The life-threatening Immunodeficiency, Centromeric Instability and Facial Anomalies (ICF) syndrome is a genetically heterogeneous autosomal recessive disorder. Twenty percent of patients cannot be explained by mutations in the known ICF genes DNA methyltransferase 3B or zinc-finger and BTB domain containing 24. Here we report mutations in the cell division cycle associated 7 and the helicase, lymphoid-specific genes in 10 unexplained ICF cases. Our data highlight the genetic heterogeneity of ICF syndrome; however, they provide evidence that all genes act in common or converging pathways leading to the ICF phenotype.</p>
      </abstract>
      <abstract abstract-type="web-summary">
        <p>
<inline-graphic id="i1" xlink:href="ncomms8870-i1.jpg"/>Immunodeficiency-centromeric instability-facial anomalies syndrome is a life threatening autosomal recessive disorder caused by mutations in <italic>DNMT3B</italic> and <italic>ZBTB24</italic>. Here Thijssen <italic>et al.</italic> identify mutations in <italic>CDCA7</italic> and <italic>HELLS</italic> in previously unexplained cases.</p>
      </abstract>
    </article-meta>
  </front>
  <body>
    <p>Immunodeficiency, Centromeric Instability and Facial Anomalies (ICF) syndrome is characterized by recurrent and often fatal respiratory and gastrointestinal infections as a consequence of hypo- or a-gammaglobulinemia in the presence of B cells<xref ref-type="bibr" rid="b1">1</xref><xref ref-type="bibr" rid="b2">2</xref>. Nearly all patients also present with distinct facial anomalies, including hypertelorism, flat nasal bridge and epicanthus<xref ref-type="bibr" rid="b1">1</xref><xref ref-type="bibr" rid="b2">2</xref>. Centromeric instability is the cytogenetic hallmark of ICF syndrome. It involves the juxtacentromeric heterochromatin repeats on chromosomes 1, 9 and 16 and is comparable to what is observed after treatment of cells with demethylating agents<xref ref-type="bibr" rid="b3">3</xref><xref ref-type="bibr" rid="b4">4</xref>. Therefore, CpG hypomethylation of juxtacentromeric satellite types II and III is a diagnostic for ICF syndrome, with additional hypomethylation of centromeric Î±-satellite repeats in <italic>DNMT3B</italic> mutation-negative patients<xref ref-type="bibr" rid="b5">5</xref><xref ref-type="bibr" rid="b6">6</xref>.</p>
    <p>Mutations in the DNA methyltransferase 3B (<italic>DNMT3B</italic>) gene (OMIM 602900; ICF1) account for â¼50% of ICF cases, while â¼30% of cases have mutations in the zinc-finger and BTB domain containing 24 (<italic>ZBTB24</italic>) gene (OMIM 614064; ICF2)<xref ref-type="bibr" rid="b2">2</xref><xref ref-type="bibr" rid="b5">5</xref>. <italic>DNMT3B</italic> is a <italic>de novo</italic> DNA methyltransferase, primarily acting during early development with a preference for CpG dense regions<xref ref-type="bibr" rid="b7">7</xref>. ICF1 mutations in the catalytic domain of <italic>DNMT3B</italic> result in largely reduced methyltransferase activity<xref ref-type="bibr" rid="b8">8</xref><xref ref-type="bibr" rid="b9">9</xref>. The function of <italic>ZBTB24</italic> is unknown, but it belongs to a family of ZBTB proteins of which many have regulatory roles in haematopoietic differentiation<xref ref-type="bibr" rid="b10">10</xref><xref ref-type="bibr" rid="b11">11</xref>. Despite the successful identification of ICF genes, the pathophysiological mechanism underlying the syndrome remains largely unresolved.</p>
    <p>Previous studies indicated further genetic heterogeneity in ICF syndrome<xref ref-type="bibr" rid="b2">2</xref>. To identify the genetic cause in genetically unexplained cases (ICFX), we combined homozygosity mapping with whole-exome sequencing. By using an autosomal recessive inheritance model and prioritizing homozygous variants in consanguineous families, we now identify four different homozygous and potentially damaging variants in the cell division cycle associated 7 (<italic>CDCA7</italic>) gene in five ICFX patients (now referred to as ICF3). In an additional five ICFX patients, we identify compound heterozygous and homozygous variants in the helicase, lymphoid-specific (<italic>HELLS</italic>) gene (ICF4). We show that knockdown of both new ICF genes leads to hypomethylation of juxtacentromeric heterochromatin repeats in a murine cell model. Our results emphasize the genetic heterogeneity of ICF syndrome, nonetheless providing evidence that all four ICF genes are involved in at least one common pathway.</p>
    <sec disp-level="1">
      <title>Results</title>
      <sec disp-level="2">
        <title>Missense mutations in <italic>CDCA7</italic> cause ICF syndrome type 3</title>
        <p>We selected 13 ICFX patients from 11 families, negative for mutations in <italic>DNMT3B</italic> or <italic>ZBTB24</italic>, of whom the clinicopathological characteristics are listed in <xref ref-type="supplementary-material" rid="S1">Supplementary Table 1</xref>. Hypomethylation of pericentromeric satellite type II (Sat II), common to all ICF patients, and centromeric Î±-satellite DNA repeats, shown to be affected only in ICF2 and ICFX, was shown before for a subset of patients<xref ref-type="bibr" rid="b2">2</xref><xref ref-type="bibr" rid="b5">5</xref><xref ref-type="bibr" rid="b6">6</xref><xref ref-type="bibr" rid="b12">12</xref>. For an additional set of ICFX patients, we confirmed Sat II and Î±-satellite hypomethylation using Southern blot analysis (<xref ref-type="supplementary-material" rid="S1">Supplementary Fig. 1</xref>). In five ICFX patients from four families we identified and confirmed homozygous missense mutations in <italic>CDCA7,</italic> all near the first two zinc-finger motifs in the conserved carboxyterminal 4-CXXC-type zinc-finger domain (<xref ref-type="fig" rid="f1">Fig. 1aâe</xref>). Segregation with disease was confirmed in family D and all mutations were predicted to be pathogenic and have an allele frequency supporting pathogenicity (<xref ref-type="fig" rid="f1">Fig. 1e</xref>, <xref ref-type="supplementary-material" rid="S1">Supplementary Table 1</xref>). <italic>CDCA7</italic> is involved in neoplastic transformation, <italic>MYC</italic>-dependent apoptosis and haematopoietic stem cell emergence; however, its molecular function is unknown<xref ref-type="bibr" rid="b13">13</xref><xref ref-type="bibr" rid="b14">14</xref>. All four zinc-finger motifs are completely conserved in the highly homologous 4-CXXC zinc-finger domain of the transcriptional repressor <italic>CDCA7-Like</italic> (<italic>CDCA7L</italic>; <xref ref-type="supplementary-material" rid="S1">Supplementary Fig. 2</xref>). The repressive activity of CDCA7L is dependent on its 4-CXXC domain, and by homology <italic>CDCA7</italic> mutations in ICF3 may disrupt a similar function<xref ref-type="bibr" rid="b15">15</xref>.</p>
      </sec>
      <sec disp-level="2">
        <title>Mutations in HELLS cause ICF syndrome type 4</title>
        <p>In an additional five ICFX patients from four families, we identified mutations in <italic>HELLS</italic> that were predicted to be pathogenic and with allele frequencies supporting pathogenicity (<xref ref-type="fig" rid="f2">Fig. 2a</xref>, <xref ref-type="supplementary-material" rid="S1">Supplementary Table 1</xref>, ICF4). In affected members of family E, we identified a missense mutation in the conserved helicase domain (c.2096A&gt;G;p.[Gln699Arg]) and an intronic mutation leading to destruction of the splice donor site in intron 5 (c.370+2T&gt;A; <xref ref-type="fig" rid="f2">Fig. 2b</xref>). Different allelic origin is supported by analysis of maternal DNA, which carried only the splice site mutation (<xref ref-type="fig" rid="f2">Fig. 2c</xref>). To analyse the effect of the lost splice donor site on mRNA processing, fibroblasts of both patients were treated with cycloheximide to inhibit nonsense-mediated decay. Upon treatment, reverse transcriptaseâPCR (RTâPCR) analysis showed increased levels of a splice variant with complete skipping of exon 5, leading to a frameshift followed by a premature stop codon in exon 6 (<xref ref-type="fig" rid="f2">Fig. 2c</xref>).</p>
        <p>The patient in family F carries a homozygous out-of-frame deletion (c.2283_2286delGTCT;p.[Ser762Argfs*4]), resulting in a frameshift and introduction of a premature stop codon in exon 20. The unaffected siblings 2.1 and 2.3 were found to be heterozygous for the deletion or homozygous for the wild-type allele, respectively (<xref ref-type="fig" rid="f2">Fig. 2d</xref>). In family G we found a deleterious homozygous in-frame deletion in the C-terminal domain of <italic>HELLS</italic>, leading to the deletion of Leucine 801 (c.2400_2402delGTT;p.[Leu801del]; <xref ref-type="fig" rid="f2">Fig. 2e</xref>). The proband of family H carries a nonsense mutation (c.610A&gt;T;p.[Lys204*]) and a duplication causing the insertion of a stop codon (c.374_381dup;p.[Lys128*]), suggesting that absence of HELLS is compatible with human life, whereas <italic>Hells</italic><sup>â/â</sup> mice die perinatally<xref ref-type="bibr" rid="b16">16</xref>. Different allelic origin of the mutations was confirmed in parental DNA (<xref ref-type="fig" rid="f2">Fig. 2f</xref>).</p>
      </sec>
      <sec disp-level="2">
        <title>ICF genes converge at centromeric DNA methylation regulation</title>
        <p>In mouse, HELLS is required for T-cell proliferation and mediates <italic>de novo</italic> DNA methylation, through its interaction with DNMT3B, dependent on its ATPase domain<xref ref-type="bibr" rid="b16">16</xref><xref ref-type="bibr" rid="b17">17</xref><xref ref-type="bibr" rid="b18">18</xref><xref ref-type="bibr" rid="b19">19</xref>. Genome-wide loss of CpG methylation, including centromeric repeats, has been observed in <italic>Hells</italic><sup>â/â</sup> mice, reminiscent of what has been described in <italic>Dnmt3b</italic> knockout mice and in mouse models for ICF1 (refs <xref ref-type="bibr" rid="b20">20</xref>, <xref ref-type="bibr" rid="b21">21</xref>). We show that transient depletion of HELLS, CDCA7 and ZBTB24, but not DNMT3B, resulted in decreased CpG methylation at centromeric repeats in wild-type mouse embryonic fibroblasts (MEFs, <xref ref-type="fig" rid="f2">Fig. 2g</xref>, <xref ref-type="supplementary-material" rid="S1">Supplementary Fig 3a,b</xref>). This confirms that DNMT3B acts during establishment of centromeric CpG methylation<xref ref-type="bibr" rid="b22">22</xref>. Moreover, it supports a role for ZBTB24 and CDCA7 in maintenance of CpG methylation at centromeric repeats, and, combined with previously published work, suggests that HELLS may be involved in both processes<xref ref-type="bibr" rid="b19">19</xref>.</p>
        <p>By identifying two new ICF syndrome genes this study highlights the genetic heterogeneity of the syndrome. The identification of at least one additional disease gene is expected with still a few cases remaining genetically unresolved. The complex, but highly overlapping, pathophysiology suggests that all ICF genes act in common or converging pathways involved in immunity, chromatin regulation and development. Convergence is supported by hypomethylation of pericentromeric repeats, which is common to all ICF subgroups, however the result of different defective pathways in the establishment and/or maintenance of CpG methylation.</p>
      </sec>
    </sec>
    <sec disp-level="1">
      <title>Methods</title>
      <sec disp-level="2">
        <title>Patients</title>
        <p>All samples were obtained in an anonymized manner, and all families gave consent for genetic analyses. The study was approved by the Medical Ethical Committee of the Leiden University Medical Center, the local ethics committee of Necker-Enfants Malades Hospital, Paris, France and the Kyushu University Institutional Review Board for Human Genome/Gene Research. The patient from family A (referred to as patient 2 in ref. <xref ref-type="bibr" rid="b23">23</xref>), patients from families B and C (referred to as pC and pS, respectively, in ref. <xref ref-type="bibr" rid="b12">12</xref>), patient 2.2 from family D and the patients in family E (referred to as P4 and P8/P9 in ref. <xref ref-type="bibr" rid="b5">5</xref>), as well as the three remaining ICFX cases (referred to as pN and P1 in ref. <xref ref-type="bibr" rid="b12">12</xref> and P4 in ref. <xref ref-type="bibr" rid="b24">24</xref>) all show typical clinical features of ICF syndrome including hypo- or agammaglobulinemia in the presence of B cells, combined with the classical cytogenetic abnormalities involving chromosomes 1, 9 and 16, and hypomethylation of Î±-satellite DNA in addition to Sat II hypomethylation. The critical features of all patients are summarized in <xref ref-type="supplementary-material" rid="S1">Supplementary Table 1</xref>; further details can be found in previous descriptions of these patients<xref ref-type="bibr" rid="b2">2</xref><xref ref-type="bibr" rid="b5">5</xref><xref ref-type="bibr" rid="b6">6</xref><xref ref-type="bibr" rid="b12">12</xref><xref ref-type="bibr" rid="b23">23</xref><xref ref-type="bibr" rid="b24">24</xref>.</p>
      </sec>
      <sec disp-level="2">
        <title>Gene identification by homozygosity mapping and sequencing</title>
        <p>Homozygosity mapping was performed using the Sentrix HumanHap-300 Genotyping BeadChips (Illumina). To this end, 750-ng genomic DNA was processed with the Infinium II Whole-Genome Genotyping Assay (Illumina). After DNA amplification, fragmentation, precipitation and resuspension, DNA was applied to the BeadChip and incubated overnight, followed by enzymatic base extension, fluorescent staining of the beads and detection of fluorescent intensities using the BeadArray Reader (Illumina). To identify regions of homozygosity, B allele frequencies were assessed for all single-nucleotide polymorphisms using BeadStudio version 3.2 (Illumina). For a subset of patients, whole-exome sequencing was performed in the Neuromics project by deCODE Genetics (ReykjavikâIceland) and analysed using deCODE Clinical Sequence Miner. Recessive analysis for multiple cases and controls and gene variant effect count (with variant effect predictor consequences moderate to high) were used to identify possible recessive mutations. For an additional set of patients, DNA libraries for whole-exome sequencing were constructed using the SureSelect Human All Exon V5 kit (Agilent Technologies) according to the manufacturerâs instructions. Sequencing was performed on the Illumina HiSeq2500 platform to generate 100âbp paired-end reads. Reads were mapped to the reference human genome (UCSC hg19) with the Burrows-Wheeler Alignment tool (BWA v0.7.4)<xref ref-type="bibr" rid="b25">25</xref>. Duplicate reads were removed by Picard (v1.87). We called SNVs and indels using the Genome Analysis Toolkit (GATK v2.5-2)<xref ref-type="bibr" rid="b26">26</xref>. Annotations of variants were made using Annotate Variation (ANNOVAR)<xref ref-type="bibr" rid="b27">27</xref>. For confirmation, relevant exons and flanking sequences of <italic>CDCA7</italic> and <italic>HELLS</italic> were amplified using standard PCR; products were purified and analysed using Sanger sequencing. Sequence tracks were analysed and visualized using ContigExpress (Vector NTI, Invitrogen-Life Technologies). PCR primers are listed in <xref ref-type="supplementary-material" rid="S1">Supplementary Table 2</xref>.</p>
      </sec>
      <sec disp-level="2">
        <title>Cycloheximide treatment and RTâPCR analysis</title>
        <p>Early-passage (<italic>P</italic>&lt;6) patient-derived primary fibroblasts were maintained in DMEM F12 (31331) supplemented with 20% heat-inactivated fetal calf serum, 1% penicillinâstreptomycin, 1% sodium pyruvate and 1% HEPES (all Invitrogen-Life Technologies). Cells were treated with 250âÎ¼gâml<sup>â1</sup> cycloheximide (dissolved in ethanol, 01810, Sigma-Aldrich) for 4âh using equal volumes of ethanol as control. After treatment, cells were harvested in Qiazol lysis reagent and RNA was isolated using the miRNeasy mini kit (both Qiagen) all according to the manufacturerâs instructions. Total RNA (2âÎ¼g) was used for random primed cDNA synthesis using the RevertAid first-strand cDNA synthesis kit (Thermo Scientific). Transcripts were amplified using standard PCR with primers listed in <xref ref-type="supplementary-material" rid="S1">Supplementary Table 2</xref>, separated by standard gel electrophoresis and sequenced by Sangerâs sequencing.</p>
      </sec>
      <sec disp-level="2">
        <title>Knockdown of gene expression in MEFs</title>
        <p>The use of animal work has been reviewed by the Animal Experimentation Ethical Committee Buffon (CEEA-40), Paris, France, and was approved under the number CEB-06-2012. Female C57BL/6N pregnant mice, aged 3â6 months, were killed at 12.5 days post conception, and individual MEF clones were isolated from each embryo of the litter. Primary MEFs were cultivated for no more than two to three passages in complete media (DMEM glutamax supplemented with 10% fetal bovine serum, 100âUâml<sup>â1</sup> penicillin, 100âÎ¼gâml<sup>â1</sup> streptomycin, all from Life Technologies). Two rounds of transfection with synthetic short interfering RNAs (siRNAs) at a final concentration of 20ânM were performed using Interferin transfection reagent (Polyplus transfection) following the manufacturerâs instructions: a first round on MEFs in suspension and the second when cells were allowed to adhere to the plate. Cells were collected after 48âh for genomic DNA extraction. Sequences of siRNAs used in the study are listed in <xref ref-type="supplementary-material" rid="S1">Supplementary Table 2</xref>.</p>
      </sec>
      <sec disp-level="2">
        <title>Satellite DNA methylation analysis using Southern blot analysis</title>
        <p>Satellite II and Î±-satellite methylation in whole-blood DNA was analysed using Southern blot analysis of 2âÎ¼g genomic DNA digested with methylation-sensitive restriction enzymes HhaI for analysis of Sat-Î± or BstBI for analysis of Satellite II repeats. Both enzymes were purchased from Fermentas. After overnight digestion, DNA was separated by electrophoresis using 0.8% agarose gels. DNA was transferred overnight to Hybond-N+ membranes (GE Healthcare) and hybridized with a radioactive probe recognizing the Î±-satellite and satellite II repeats, respectively. Signals were detected by phosphoimaging or by exposure to X-ray films. For analysis of murine satellite repeats, genomic DNA was extracted and purified from MEFs using the NucleoSpin Tissue kit (Macherey-Nagel) according to the manufacturerâs instructions. The DNA pellet was eluted in Tris EDTA buffer containing 20âÎ¼gâml<sup>â1</sup> RNAse A. Genomic DNA from MEFs (500âng) was digested with 20 units of MspI or HpaII (New England Biolabs) for 16âh to analyse the DNA methylation patterns of centromeric minor satellite repeats. The digested DNA fragments were separated by electrophoresis using 1% agarose gels and transferred overnight to Hybond-N+ membranes (GE Healthcare) in 20 Ã SSC. After ultraviolet crosslink, the membranes were pre-hybridized in 6 Ã SSC, 5 Ã Denhardt and 0.1% SDS and then hybridized with 32P-labelled minor satellite oligonucleotide probe: (5â²-ACATTCGTTGGAAACGGGATTTGTAGAACAGTGTATATCAATGAGTTACAATGAGAAACAT-3â²).</p>
        <p>Pre-hybridization and hybridization were carried out at 42âÂ°C for 1âh. The membranes were washed three times in 6 Ã SSC and 0.1% SDS at 37âÂ°C and signals were detected by phosphorimaging using FLA 7000 phosphorimager (Fuji). Uncropped scans of the Southern blots are presented in <xref ref-type="supplementary-material" rid="S1">Supplementary Figs 4 and 5</xref>.</p>
      </sec>
      <sec disp-level="2">
        <title>Quantification of knockdown efficiency using qRTâPCR</title>
        <p>Total RNA from MEFs was isolated using TRIzol Reagent (Life Technologies) according to the manufacturerâs instructions. Contaminant genomic DNA was eliminated with TURBO DNA-free kit (Ambion). Reverse transcription was carried out using 1âÎ¼g DNA-free RNA and 50âÎ¼M random hexamers, 20âU of RNase Out and 100âU of RevertAid reverse transcriptase (Life Technologies). Complementary DNA reactions were used as templates for PCR reactions. Real-time PCR was performed using the light cycler-DNA MasterPLUS SYBR Green I mix (Thermo Scientific) supplemented with 0.5âÎ¼M of specific primer pairs (listed in <xref ref-type="supplementary-material" rid="S1">Supplementary Table 2</xref>). Real-time qPCRs were run on a light cycler rapid thermal system (Light Cycler 480 2.0 Real time PCR system, Roche) with 20âs of denaturation at 95âÂ°C, 20âs of annealing at 60âÂ°C and 20âs of extension at 72âÂ°C for all primers, and analysed by the comparative CT (âµ<italic>C</italic><sub>t</sub>) method.</p>
      </sec>
    </sec>
    <sec disp-level="1">
      <title>Additional information</title>
      <p><bold>How to cite this article:</bold> Thijssen, P. E. <italic>et al.</italic> Mutations in <italic>CDCA7</italic> and <italic>HELLS</italic> cause immunodeficiencyâcentromeric instabilityâfacial anomalies syndrome. <italic>Nat. Commun.</italic> 6:7870 doi: 10.1038/ncomms8870 (2015).</p>
    </sec>
    <sec sec-type="supplementary-material" id="S1">
      <title>Supplementary Material</title>
      <supplementary-material id="d32e18" content-type="local-data">
        <caption>
          <title>Supplementary Information</title>
          <p>Supplementary Figures 1-5 and Supplementary Tables 1-2</p>
        </caption>
        <media xlink:href="ncomms8870-s1.pdf"/>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack>
      <p>We thank all patients and their families for their consent to contribute to our study. We thank K. Ichiyanagi and L. Daxinger for helpful advice, staff of the Kyushu University International Legal Office for help in legal and ethical affairs, and T.P. Pham, S.L. HÃ¶cker, M. Miyake and H. Furuumi for technical assistance. This work was supported by KAKENHI (22134006, 23249019 and 26253020), the National Institutes of Health/National Institute of Allergy and Infectious Diseases (R21 AI090135), European Communityâs Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 2012-305121 âIntegrated Europeanâomics research project for diagnosis and therapy in rare neuromuscular and neurodegenerative diseases (NEUROMICS)â and French National Research AgencyâProgram on physiopathology of rare diseases (ANR-09-GENO-035).</p>
    </ack>
    <ref-list>
      <ref id="b1">
        <mixed-citation publication-type="journal"><name><surname>Hagleitner</surname><given-names>M. M.</given-names></name>
<italic>et al.</italic>
<article-title>Clinical spectrum of immunodeficiency, centromeric instability and facial dysmorphism (ICF syndrome)</article-title>. <source>J. Med. Genet.</source>
<volume>45</volume>, <fpage>93</fpage>â<lpage>99</lpage> (<year>2008</year>).<pub-id pub-id-type="pmid">17893117</pub-id></mixed-citation>
      </ref>
      <ref id="b2">
        <mixed-citation publication-type="journal"><name><surname>Weemaes</surname><given-names>C. M.</given-names></name>
<italic>et al.</italic>
<article-title>Heterogeneous clinical presentation in ICF syndrome: correlation with underlying gene defects</article-title>. <source>Eur. J. Hum. Genet.</source>
<volume>21</volume>, <fpage>1219</fpage>â<lpage>1225</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">23486536</pub-id></mixed-citation>
      </ref>
      <ref id="b3">
        <mixed-citation publication-type="journal"><name><surname>Jeanpierre</surname><given-names>M.</given-names></name>
<italic>et al.</italic>
<article-title>An embryonic-like methylation pattern of classical satellite DNA is observed in ICF syndrome</article-title>. <source>Hum. Mol. Genet</source>
<volume>2</volume>, <fpage>731</fpage>â<lpage>735</lpage> (<year>1993</year>).<pub-id pub-id-type="pmid">8102570</pub-id></mixed-citation>
      </ref>
      <ref id="b4">
        <mixed-citation publication-type="journal"><name><surname>Tiepolo</surname><given-names>L.</given-names></name>
<italic>et al.</italic>
<article-title>Multibranched chromosomes 1, 9, and 16 in a patient with combined IgA and IgE deficiency</article-title>. <source>Hum. Genet.</source>
<volume>51</volume>, <fpage>127</fpage>â<lpage>137</lpage> (<year>1979</year>).<pub-id pub-id-type="pmid">511139</pub-id></mixed-citation>
      </ref>
      <ref id="b5">
        <mixed-citation publication-type="journal"><name><surname>de Greef</surname><given-names>J. C.</given-names></name>
<italic>et al.</italic>
<article-title>Mutations in ZBTB24 are associated with immunodeficiency, centromeric instability, and facial anomalies syndrome type 2</article-title>. <source>Am. J. Hum. Genet.</source>
<volume>88</volume>, <fpage>796</fpage>â<lpage>804</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">21596365</pub-id></mixed-citation>
      </ref>
      <ref id="b6">
        <mixed-citation publication-type="journal"><name><surname>Jiang</surname><given-names>Y. L.</given-names></name>
<italic>et al.</italic>
<article-title>DNMT3B mutations and DNA methylation defect define two types of ICF syndrome</article-title>. <source>Hum. Mutat.</source>
<volume>25</volume>, <fpage>56</fpage>â<lpage>63</lpage> (<year>2005</year>).<pub-id pub-id-type="pmid">15580563</pub-id></mixed-citation>
      </ref>
      <ref id="b7">
        <mixed-citation publication-type="journal"><name><surname>Auclair</surname><given-names>G.</given-names></name>, <name><surname>Guibert</surname><given-names>S.</given-names></name>, <name><surname>Bender</surname><given-names>A.</given-names></name> &amp; <name><surname>Weber</surname><given-names>M.</given-names></name>
<article-title>Ontogeny of CpG island methylation and specificity of DNMT3 methyltransferases during embryonic development in the mouse</article-title>. <source>Genome Biol.</source>
<volume>15</volume>, <fpage>545</fpage> (<year>2014</year>).<pub-id pub-id-type="pmid">25476147</pub-id></mixed-citation>
      </ref>
      <ref id="b8">
        <mixed-citation publication-type="journal"><name><surname>Gowher</surname><given-names>H.</given-names></name> &amp; <name><surname>Jeltsch</surname><given-names>A.</given-names></name>
<article-title>Molecular enzymology of the catalytic domains of the Dnmt3a and Dnmt3b DNA methyltransferases</article-title>. <source>J. Biol. Chem.</source>
<volume>277</volume>, <fpage>20409</fpage>â<lpage>20414</lpage> (<year>2002</year>).<pub-id pub-id-type="pmid">11919202</pub-id></mixed-citation>
      </ref>
      <ref id="b9">
        <mixed-citation publication-type="journal"><name><surname>Moarefi</surname><given-names>A. H.</given-names></name> &amp; <name><surname>Chedin</surname><given-names>F.</given-names></name>
<article-title>ICF syndrome mutations cause a broad spectrum of biochemical defects in DNMT3B-mediated <italic>de novo</italic> DNA methylation</article-title>. <source>J. Mol. Biol.</source>
<volume>409</volume>, <fpage>758</fpage>â<lpage>772</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">21549127</pub-id></mixed-citation>
      </ref>
      <ref id="b10">
        <mixed-citation publication-type="journal"><name><surname>Nitta</surname><given-names>H.</given-names></name>
<italic>et al.</italic>
<article-title>Three novel ZBTB24 mutations identified in Japanese and Cape Verdean type 2 ICF syndrome patients</article-title>. <source>J. Hum. Genet.</source>
<volume>58</volume>, <fpage>455</fpage>â<lpage>460</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">23739126</pub-id></mixed-citation>
      </ref>
      <ref id="b11">
        <mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>S. U.</given-names></name> &amp; <name><surname>Maeda</surname><given-names>T.</given-names></name>
<article-title>POK/ZBTB proteins: an emerging family of proteins that regulate lymphoid development and function</article-title>. <source>Immunol. Rev.</source>
<volume>247</volume>, <fpage>107</fpage>â<lpage>119</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22500835</pub-id></mixed-citation>
      </ref>
      <ref id="b12">
        <mixed-citation publication-type="journal"><name><surname>Velasco</surname><given-names>G.</given-names></name>
<italic>et al.</italic>
<article-title>Germline genes hypomethylation and expression define a molecular signature in peripheral blood of ICF patients: implications for diagnosis and etiology</article-title>. <source>Orphanet. J. Rare. Dis.</source>
<volume>9</volume>, <fpage>56</fpage> (<year>2014</year>).<pub-id pub-id-type="pmid">24742017</pub-id></mixed-citation>
      </ref>
      <ref id="b13">
        <mixed-citation publication-type="journal"><name><surname>Gill</surname><given-names>R. M.</given-names></name>, <name><surname>Gabor</surname><given-names>T. V.</given-names></name>, <name><surname>Couzens</surname><given-names>A. L.</given-names></name> &amp; <name><surname>Scheid</surname><given-names>M. P.</given-names></name>
<article-title>The MYC-associated protein CDCA7 is phosphorylated by AKT to regulate MYC-dependent apoptosis and transformation</article-title>. <source>Mol. Cell Biol.</source>
<volume>33</volume>, <fpage>498</fpage>â<lpage>513</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">23166294</pub-id></mixed-citation>
      </ref>
      <ref id="b14">
        <mixed-citation publication-type="journal"><name><surname>Guiu</surname><given-names>J.</given-names></name>
<italic>et al.</italic>
<article-title>Identification of Cdca7 as a novel Notch transcriptional target involved in hematopoietic stem cell emergence</article-title>. <source>J. Exp. Med.</source>
<volume>211</volume>, <fpage>2411</fpage>â<lpage>2423</lpage> (<year>2014</year>).<pub-id pub-id-type="pmid">25385755</pub-id></mixed-citation>
      </ref>
      <ref id="b15">
        <mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>K.</given-names></name>, <name><surname>Ou</surname><given-names>X. M.</given-names></name>, <name><surname>Wu</surname><given-names>J. B.</given-names></name> &amp; <name><surname>Shih</surname><given-names>J. C.</given-names></name>
<article-title>Transcription factor E2F-associated phosphoprotein (EAPP), RAM2/CDCA7L/JPO2 (R1), and simian virus 40 promoter factor 1 (Sp1) cooperatively regulate glucocorticoid activation of monoamine oxidase B</article-title>. <source>Mol. Pharmacol.</source>
<volume>79</volume>, <fpage>308</fpage>â<lpage>317</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">20980443</pub-id></mixed-citation>
      </ref>
      <ref id="b16">
        <mixed-citation publication-type="journal"><name><surname>Geiman</surname><given-names>T. M.</given-names></name> &amp; <name><surname>Muegge</surname><given-names>K.</given-names></name>
<article-title>Lsh, an SNF2/helicase family member, is required for proliferation of mature T lymphocytes</article-title>. <source>Proc. Natl Acad. Sci. USA</source>
<volume>97</volume>, <fpage>4772</fpage>â<lpage>4777</lpage> (<year>2000</year>).<pub-id pub-id-type="pmid">10781083</pub-id></mixed-citation>
      </ref>
      <ref id="b17">
        <mixed-citation publication-type="journal"><name><surname>Ren</surname><given-names>J.</given-names></name>
<italic>et al.</italic>
<article-title>The ATP binding site of the chromatin remodeling homolog Lsh is required for nucleosome density and de novo DNA methylation at repeat sequences</article-title>. <source>Nucleic Acids Res.</source>
<volume>43</volume>, <fpage>1444</fpage>â<lpage>1455</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">25578963</pub-id></mixed-citation>
      </ref>
      <ref id="b18">
        <mixed-citation publication-type="journal"><name><surname>Yu</surname><given-names>W.</given-names></name>
<italic>et al.</italic>
<article-title>Genome-wide DNA methylation patterns in LSH mutant reveals de-repression of repeat elements and redundant epigenetic silencing pathways</article-title>. <source>Genome Res.</source>
<volume>24</volume>, <fpage>1613</fpage>â<lpage>1623</lpage> (<year>2014</year>).<pub-id pub-id-type="pmid">25170028</pub-id></mixed-citation>
      </ref>
      <ref id="b19">
        <mixed-citation publication-type="journal"><name><surname>Zhu</surname><given-names>H.</given-names></name>
<italic>et al.</italic>
<article-title>Lsh is involved in <italic>de novo</italic> methylation of DNA</article-title>. <source>EMBO J.</source>
<volume>25</volume>, <fpage>335</fpage>â<lpage>345</lpage> (<year>2006</year>).<pub-id pub-id-type="pmid">16395332</pub-id></mixed-citation>
      </ref>
      <ref id="b20">
        <mixed-citation publication-type="journal"><name><surname>Ueda</surname><given-names>Y.</given-names></name>
<italic>et al.</italic>
<article-title>Roles for Dnmt3b in mammalian development: a mouse model for the ICF syndrome</article-title>. <source>Development</source>
<volume>133</volume>, <fpage>1183</fpage>â<lpage>1192</lpage> (<year>2006</year>).<pub-id pub-id-type="pmid">16501171</pub-id></mixed-citation>
      </ref>
      <ref id="b21">
        <mixed-citation publication-type="journal"><name><surname>Velasco</surname><given-names>G.</given-names></name>
<italic>et al.</italic>
<article-title>Dnmt3b recruitment through E2F6 transcriptional repressor mediates germ-line gene silencing in murine somatic tissues</article-title>. <source>Proc. Natl Acad. Sci. USA</source>
<volume>107</volume>, <fpage>9281</fpage>â<lpage>9286</lpage> (<year>2010</year>).<pub-id pub-id-type="pmid">20439742</pub-id></mixed-citation>
      </ref>
      <ref id="b22">
        <mixed-citation publication-type="journal"><name><surname>Okano</surname><given-names>M.</given-names></name>, <name><surname>Bell</surname><given-names>D. W.</given-names></name>, <name><surname>Haber</surname><given-names>D. A.</given-names></name> &amp; <name><surname>Li</surname><given-names>E.</given-names></name>
<article-title>DNA methyltransferases Dnmt3a and Dnmt3b are essential for <italic>de novo</italic> methylation and mammalian development</article-title>. <source>Cell</source>
<volume>99</volume>, <fpage>247</fpage>â<lpage>257</lpage> (<year>1999</year>).<pub-id pub-id-type="pmid">10555141</pub-id></mixed-citation>
      </ref>
      <ref id="b23">
        <mixed-citation publication-type="journal"><name><surname>Kloeckener-Gruissem</surname><given-names>B.</given-names></name>, <name><surname>Betts</surname><given-names>D. R.</given-names></name>, <name><surname>Zankl</surname><given-names>A.</given-names></name>, <name><surname>Berger</surname><given-names>W.</given-names></name> &amp; <name><surname>Gungor</surname><given-names>T.</given-names></name>
<article-title>A new and a reclassified ICF patient without mutations in DNMT3B and its interacting proteins SUMO-1 and UBC9</article-title>. <source>Am. J. Med. Genet. A</source>
<volume>136</volume>, <fpage>31</fpage>â<lpage>37</lpage> (<year>2005</year>).<pub-id pub-id-type="pmid">15952214</pub-id></mixed-citation>
      </ref>
      <ref id="b24">
        <mixed-citation publication-type="journal"><name><surname>Kubota</surname><given-names>T.</given-names></name>
<italic>et al.</italic>
<article-title>ICF syndrome in a girl with DNA hypomethylation but without detectable DNMT3B mutation</article-title>. <source>Am. J. Med. Genet. A</source>
<volume>129A</volume>, <fpage>290</fpage>â<lpage>293</lpage> (<year>2004</year>).<pub-id pub-id-type="pmid">15326630</pub-id></mixed-citation>
      </ref>
      <ref id="b25">
        <mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>H.</given-names></name> &amp; <name><surname>Durbin</surname><given-names>R.</given-names></name>
<article-title>Fast and accurate long-read alignment with Burrows-Wheeler transform</article-title>. <source>Bioinformatics</source>
<volume>26</volume>, <fpage>589</fpage>â<lpage>595</lpage> (<year>2010</year>).<pub-id pub-id-type="pmid">20080505</pub-id></mixed-citation>
      </ref>
      <ref id="b26">
        <mixed-citation publication-type="journal"><name><surname>McKenna</surname><given-names>A.</given-names></name>
<italic>et al.</italic>
<article-title>The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data</article-title>. <source>Genome Res.</source>
<volume>20</volume>, <fpage>1297</fpage>â<lpage>1303</lpage> (<year>2010</year>).<pub-id pub-id-type="pmid">20644199</pub-id></mixed-citation>
      </ref>
      <ref id="b27">
        <mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>K.</given-names></name>, <name><surname>Li</surname><given-names>M.</given-names></name> &amp; <name><surname>Hakonarson</surname><given-names>H.</given-names></name>
<article-title>ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data</article-title>. <source>Nucleic Acids Res.</source>
<volume>38</volume>, <fpage>e164</fpage> (<year>2010</year>).<pub-id pub-id-type="pmid">20601685</pub-id></mixed-citation>
      </ref>
    </ref-list>
    <fn-group>
      <fn fn-type="COI-statement">
        <p>The authors declare no competing financial interests.</p>
      </fn>
      <fn>
        <p><bold>Author contributions</bold> P.E.T., Y.I., G.V., J.W., J.C.d.G., C.W., C.F., S.M.v.d.M. and H.S. conceived and designed the experiments; P.E.T., Y.I., G.G., J.W., G.V., H.N., M.Y., M.S., J.C.d.G., M.M.v.O.-T.D. and M.J.D.v.T. performed the experiments; P.T., Y.I., G.G., J.W., G.V., H.N., M.Y., M.S., Y.S., R.J.L.F.L., J.C.d.G., M.M.v.O.-T.D. and M.J.D.v.T. analysed the data; M.U., A.G., P.P., B.K.-G., T.G., I.R., C.P., K.K., B.R., T.I., T.K., M.M.v.O.-T.D., M.J.D.v.T. and C.W. contributed samples; P.T., C.F., S.M.v.d.M. and H.S. wrote the paper; C.F., S.M.v.d.M. and H.S. jointly supervised the research.</p>
      </fn>
    </fn-group>
    <fn-group content-type="nature-chghst">
      <fn fn-type="update">
        <p content-type="chgdate">06/22/2016</p>
        <p content-type="chgmade">A correction has been published and is appended to both the HTML and PDF versions of this paper. The error has not been fixed in the paper.</p>
      </fn>
    </fn-group>
  </back>
  <floats-group>
    <fig id="f1">
      <label>Figure 1</label>
      <caption>
        <title>Homozygous missense mutations in <italic>CDCA7</italic> in five ICF3 patients.</title>
        <p>(<bold>a</bold>) Schematic representation of CDCA7, with the identified homozygous missense mutations in red. Sequence outtake: 4-CXXC-type zinc-finger domain, CXXC motifs are underlined, mutated residues in red. (<bold>b</bold>â<bold>d</bold>) Sanger sequencing confirmation of missense mutations in CDCA7 in families AâC. All variants were homozygous, the reference sequence is displayed for comparison. (<bold>e</bold>) Sanger sequencing confirmation of the homozygous missense CDCA7 mutation in patients 2.2 (proband) and 2.3 of family D. Both parents are heterozygous for the variant, sibling 2.1 is unaffected and homozygous for the wild-type (wt) allele.</p>
      </caption>
      <graphic xlink:href="ncomms8870-f1"/>
    </fig>
    <fig id="f2">
      <label>Figure 2</label>
      <caption>
        <title>Mutations in <italic>HELLS</italic> in five ICF4 patients.</title>
        <p>(<bold>a</bold>) Schematic representation of HELLS, with the identified mutations in red. (<bold>b</bold>) Sanger sequencing confirmation of HELLS mutations in family E. Only c.370+2T&gt;A was identified in maternal DNA, indicating different allelic origins of both mutations, or <italic>de novo</italic> occurrence of the second mutation. (<bold>c</bold>) RTâPCR analysis of HELLS mRNA on treatment of patient-derived fibroblasts with cycloheximide (C) revealed that c.370+2T&gt;A leads to complete skipping of exon 5 and disruption of the open reading frame. Ethanol-treated samples (E) served as controls, alternative splicing was confirmed using Sangerâs sequencing in two independent experiments for both samples. (<bold>d</bold>) Sanger sequencing confirmation of a homozygous out-of-frame deletion in <italic>HELLS</italic> in family F. Both parents as well as unaffected sibling 2.1 are heterozygous for the deletion allele; unaffected sibling 2.3 is homozygous for the wt allele. (<bold>e</bold>) Sanger sequencing confirmation of a homozygous in-frame deletion in <italic>HELLS</italic> in family G. Both parents are heterozygous for the deletion allele. (<bold>f</bold>) Sanger sequencing confirmation of nonsense mutations in <italic>HELLS</italic> in family H. Different allelic origin was confirmed in parental DNA. (<bold>g</bold>) Southern blot analysis of minor satellite DNA methylation in <italic>Dnmt3b</italic><sup>â/â</sup> and siRNA-treated wt MEFs after digesting DNA with MspI or its methylation-sensitive isoschizomer HpaII revealed CpG hypomethylation on knockdown of Zbtb24, Cdca7 and Hells. Molecular weights of the 2-Log DNA size marker are in kilobasepairs.</p>
      </caption>
      <graphic xlink:href="ncomms8870-f2"/>
    </fig>
  </floats-group>
</article>

</metadata></record></GetRecord></OAI-PMH>